Literature DB >> 15464740

Effects of repeated injections of the neurotensin analog NT69L on dopamine release and uptake in rat striatum in vitro.

Rui Wang1, Mona Boules, William Tiner, Elliott Richelson.   

Abstract

The effect of five daily intraperitoneal (i.p.) injections of NT69L on in vitro dopamine release, uptake, and [(3)H]NT binding in rat striatal tissue was investigated. NT69L perfusion increased K(+)-evoked and electrically evoked [(3)H]DA release. NT receptor-1 antagonist SR48692 inhibited the stimulatory effect of NT69L on K+-evoked [(3)H]DA release, but not on electrical depolarization. Pretreatment with NT69L, in vivo, daily for 5 days, did not cause significant change in K(+) evoked [(3)H]DA release, but reduced electrically evoked [(3)H]DA release induced by NT69L perfusion. Repeated perfusion with NT69L in vitro caused marked reduction on K(+)-evoked [(3)H]DA release and no change in electrically evoked [(3)H]DA release. [(3)H]NT binding was not significantly changed by one injection but was decreased after five injections of NT69L. Desensitization to the effects of NT69L in vitro was different depending upon whether tissue was preexposed to the compound in vivo or in vitro. These results provide further proof for the involvement of different NT receptor subtypes in mediating the effect of NT69L on dopamine release evoked by K(+) or electrical depolarization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464740     DOI: 10.1016/j.brainres.2004.07.069

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  The role of NTS2 in the development of tolerance to NT69L in mouse models for hypothermia and thermal analgesia.

Authors:  Kristin E Smith; Mona Boules; Katrina Williams; Abdul H Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2011-06-21       Impact factor: 3.332

2.  The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.

Authors:  David Feifel; Gilia Melendez; Rachel J Murray; Dan N Tina Tran; Michelle A Rullan; Paul D Shilling
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

3.  The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Joanna Peris; Elliott Richelson
Journal:  Brain Res       Date:  2009-11-27       Impact factor: 3.252

4.  Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.

Authors:  Siobhan Briody; Mona Boules; Alfredo Oliveros; Irfan Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2009-10-02       Impact factor: 3.332

Review 5.  Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders.

Authors:  Chelsea A Vadnie; Jun Hyun Park; Noha Abdel Gawad; Ada Man Choi Ho; David J Hinton; Doo-Sup Choi
Journal:  Front Neurosci       Date:  2014-09-18       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.